WO2025181652 - TREATMENT OF CANCER USING ARIPIPRAZOLE AND ANTICANCER AGENT
National phase entry is expected:
Publication Number
WO/2025/181652
Publication Date
04.09.2025
International Application No.
PCT/IB2025/051963
International Filing Date
24.02.2025
Title **
[English]
TREATMENT OF CANCER USING ARIPIPRAZOLE AND ANTICANCER AGENT
[French]
TRAITEMENT DU CANCER À L'AIDE D'ARIPIPRAZOLE ET D'UN AGENT ANTICANCÉREUX
Applicants **
VSPHARM TECH CO., LTD.
Inventors
PARK, Shin Young
LEE, Hyunho
KIM, SoHee
PARK, Eun-Ran
HONG, Soon-Sun
JUNG, Kyung Hee
CHO, Yejin
Priority Data
63/558,188
27.02.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
MOIP
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2717 | |
| EPO | Filing, Examination, Granting | 15959 | |
| Japan | Filing, Examination, Granting | 2309 | |
| South Korea | Filing, Examination, Granting | 1882 | |
| USA | Filing, Examination, Granting | 5940 |
Total:
28,807
Contact Us
Abstract[English]
Aripiprazole, a compound typically used for psychiatric conditions, enhances the impact of various anticancer agents on pancreatic, glioma, colorectal, and lung cancers. By lowering levels of anti‑apoptotic proteins (e.g., XIAP, MCL‑1, cFLIP) and interfering with STAT3 signaling, it intensifies apoptotic pathways and counters drug resistance. This combined approach suppresses tumor growth without significant added toxicity, offering a more potent and better‑tolerated treatment option for aggressive malignancies.[French]
L'aripiprazole, un composé généralement utilisé pour des affections psychiatriques, améliore l'impact de divers agents anticancéreux sur le cancer du pancréas, le gliome, le cancer colorectal et le cancer du poumon. En abaissant les taux de protéines anti-apoptotiques (p. ex. XIAP, MCL-1, cFLIP) et en interférant avec la signalisation STAT3, il intensifie les voies apoptotiques et s'oppose à la résistance aux médicaments. Cette approche combinée supprime la croissance tumorale sans toxicité ajoutée significative, offrant une option de traitement plus puissante et mieux tolérée pour des tumeurs malignes agressives.